Artelo Biosciences, Inc. (NASDAQ:ARTL) was established in 2011, formerly known as Reactive Medical, Inc., changed to its current name in April 2017, headquartered in La Jolla, California, with 3 full-time employees, is a clinical A stage biopharmaceutical company, focusing on the development and commercialization of treatments to regulate the endocannabinoid system and related signaling pathways.
Artelo Biosciences, Inc. (ARTL):
Artelo Biosciences is a biopharmaceutical company focused on the development and commercialization of a diverse product portfolio of novel endocannabinoid system regulation therapies.
Artelo Biosciences product line includes:
- ART27.13, a cannabinoid agonist used to treat cancer-related anorexia;
- ART12.11, a CBD co-crystal, used to treat inflammatory bowel disease and post-traumatic stress disorder;
- ART26.12, a FABP5 inhibitor for prostate and breast cancer treatment.
Artelo Biosciences and Stony Brook University in the United States have reached a research on the FABP5 platform and obtained a global commercial license agreement for the development of leading cancer, pain and inflammation compounds.